Bortezomib is a potent proteasome inhibitor used as an anti-cancer medication in the treatment of multiple myeloma and mantle cell lymphoma. This category contains a comprehensive range of reference standards,… Read more


















































Bortezomib is a potent proteasome inhibitor used as an anti-cancer medication in the treatment of multiple myeloma and mantle cell lymphoma. This category contains a comprehensive range of reference standards, including the active pharmaceutical ingredient, its pharmacopeial and non-pharmacopeial impurities, metabolites, and stable isotope labelled compounds. These high-quality reference materials are essential tools for pharmaceutical laboratories engaged in rigorous analytical testing, method validation, and quality control. By providing precise benchmarks for impurity profiling, these standards allow for the accurate identification and quantification of process-related impurities and degradation products that may arise during drug synthesis or storage. Furthermore, stable isotope labelled versions of the drug and its related substances serve as critical internal standards in mass spectrometry-based assays, ensuring reliable and reproducible results throughout the drug development lifecycle and compliance with established regulatory guidelines.